ClinicalTrials.gg
RecruitingNCT03781492PRESAGEUpdated May 26, 2020

Stable Angina Management and Treatment

An observational study in Stable Angina and Coronary Artery Disease, sponsored by Silesian Centre for Heart Diseases. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-26.

Sponsored by Silesian Centre for Heart Diseases · Observational

How we know

From the registry’s dates

  • Started Jan 2006; still recruiting 20 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,000
Ages
18 Years and older
Sex
All
01

Study summary

The Prospective REgistry of Stable Angina manaGEment and Treatment (PRESAGE) is an observational study on an all-comer stable angina population hospitalised in a highly specialized cardiovascular centre with cardiac surgery facilities. The aim of the study is to assess the clinical characteristics, treatment modalities, early and long-term outcomes in this population.

Read the detailed description

The Prospective REgistry of Stable Angina manaGEment and Treatment (PRESAGE) is a single-center, observational study recruiting consecutive patients with stable angina, who were diagnosed and treated in the 3rd Chair and Department of Cardiology in the Silesian Centre for Heart Diseases in Zabrze, Poland. The Silesian Centre for Heart Diseases is a highly specialised cardiology centre with cardiac surgery facilities

The main objective of the PRESAGE Registry is to clarify the overall clinical characteristics of patients with stable angina, their demographics and clinical profile, current management, early and long-term outcomes, with regard to the administered treatment.

The diagnosis of stable angina was based on clinical characterization, coronary angiography, and the current guidelines of the European Society of Cardiology. Patients with vasospastic and/or microvascular angina were also included to the registry. Performance of coronary angiography is the criterion of the enrolment in the registry.

Patients with acute coronary syndromes are excluded from the analysis.

Data collection is patient-based (not event-based).

Complete patient demographics: medical history, complete hospitalization data (diagnostic and therapeutic) and in-hospital results are collected in an electronic form by the attending physician. The patients are under constant follow-up for all-cause mortality and major cardiac adverse events.

02

Conditions studied

  • Stable Angina
  • Coronary Artery Disease
03

In context

Angina, Stable

344 studies on the registry are indexed under Angina, Stable; 56 are open to participants now.

This study's planned enrollment of 25,000 is above the median of 508 across 103 observational studies indexed under Angina, Stable.

Browse Angina, Stable studies →

Lead sponsor

Silesian Centre for Heart Diseases is the lead sponsor of 17 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population is formed by all-comer patients hospitalized in cardiology ward with a diagnosis of stable angina.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • symptom based diagnosis of stable angina

Exclusion criteria

Exclusion Criteria:

  • acute coronary syndrome on admission
  • ≤ 18 years old
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of participants with reported deaths from any cause

    Time frame: From date of inclusion until the date of death from any cause, assessed up to 5 year

Secondary outcomes

  1. Number of participants with reported myocardial infarction

    Time frame: From date of inclusion until the date of first event, assessed up to 5 year

  2. Number of participants with reported cerebrovascular insult

    Time frame: From date of inclusion until the date of first event, assessed up to 5 year

  3. Number of participants with reported acute coronary syndrome driven revascularisation

    Time frame: From date of inclusion until the date of first event, assessed up to 5 year

07

Study locations

1 of 1 sites recruiting
  • 3rd Chair and Department of Cardiology of Silesian Centre for Heart Diseases
    Zabrze, Silesia 41-800, Poland
    Recruiting
    • Mariusz Gąsior, Prof, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2006 (actual). Primary completion is estimated for Dec 2026, 251 months after the start.

Of 52 observational studies under Angina, Stable, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 79. This study's planned 251 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2018
First posted
Dec 20, 2018
StartActual
Jan 1, 2006
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03781492
Lead sponsor
Silesian Centre for Heart Diseases
Responsible party
Mariusz Gasior (Clinical Professor, Silesian Centre for Heart Diseases) — Principal investigator
First posted
Dec 20, 2018
Start date
Jan 1, 2006
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 26, 2020

Study contacts

Piotr Desperak, MD
Contact
desperak.piotr@gmail.com
+48514374167

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion